{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:46:14Z","timestamp":1793159174242,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>While radioiodine therapy is commonly used for treating Graves' disease, a prolonged and clinical hypothyroidism may result in disabling symptoms leading to deterioration of quality of life (QoL) of patients. Introducing levothyroxine (LT<jats:sub>4<\/jats:sub>) treatment in the early post-therapeutic period may be an interesting approach to limit this phenomenon.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicenter, prospective, open-label randomized controlled trial enrolled 94 patients with Graves' hyperthyroidism randomly assigned to the experimental group (<jats:italic>n<\/jats:italic>=46) (group A: early prophylactic LT<jats:sub>4<\/jats:sub>treatment) or the control group (<jats:italic>n<\/jats:italic>=48) (group B: standard follow-up). The primary endpoint was the 6-month QoL. The secondary endpoints were other QoL scores such as Graves' ophthalmopathy (GO) outcomes, thyroid function tests and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The primary endpoint at 6 months was achieved: the mental composite score (MCS) of Short Form 36 (SF-36) was significantly higher in group A compared to group B (<jats:italic>P<\/jats:italic>=0.009). Four other dimension scores of the SF-36 and four dimension scores of the thyroid-specific patient-reported outcome (ThyPRO) significantly differed between the two groups, indicating better QoL in group A. After adjustment for variables, the early LT<jats:sub>4<\/jats:sub>administration strategy was found as an independent factor for only two scores of SF-36: the MCS and the general health (GH) score. There were no differences in GO, final thyroid status and changes in the anti-TSH receptor antibodies (TRAbs) levels between the two groups. No adverse cardiovascular event was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early LT<jats:sub>4<\/jats:sub>administration post-radioactive iodine (RAI) could represent a safe potential benefit for patients with regard to QoL. The optimal strategy taking into account administered RAI activities and LT<jats:sub>4<\/jats:sub>treatment dosage and timing remains to be determined.<\/jats:p><\/jats:sec>","DOI":"10.1530\/eje-15-1099","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T17:23:19Z","timestamp":1452964999000},"page":"491-502","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":22,"title":["Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study"],"prefix":"10.1093","volume":"174","author":[{"given":"David","family":"Ta\u00efeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bournaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Eberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Catargi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Schvartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-B\u00e9atrice","family":"Cavarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Faugeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Elisabeth","family":"Toubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Benisvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cendrine","family":"Archange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mundler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Esmaeel","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Baumstarck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2016022218335307000_174.4.491.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0801880"},{"key":"2016022218335307000_174.4.491.2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrendo.2013.193","article-title":"Diagnosis and management of Graves disease: a global overview","volume":"9","author":"Bartalena","year":"2013","journal-title":"Nature Reviews. Endocrinology"},{"key":"2016022218335307000_174.4.491.3","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01993"},{"key":"2016022218335307000_174.4.491.4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cen.12688","article-title":"A 2013 European survey of clinical practice patterns in the management of Graves' disease","volume":"84","author":"Bartalena","year":"2014","journal-title":"Clinical Endocrinology"},{"key":"2016022218335307000_174.4.491.5","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1998.8.653"},{"key":"2016022218335307000_174.4.491.6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.593"},{"key":"2016022218335307000_174.4.491.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)12295-X"},{"key":"2016022218335307000_174.4.491.8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ijc.2910500611","article-title":"Cancer mortality after iodine-131 therapy for hyperthyroidism","volume":"50","author":"Hall","year":"1992","journal-title":"International Journal of Cancer"},{"key":"2016022218335307000_174.4.491.9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22635"},{"key":"2016022218335307000_174.4.491.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.4.347"},{"key":"2016022218335307000_174.4.491.11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.3.1073"},{"key":"2016022218335307000_174.4.491.12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/eje.0.1410117","article-title":"Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome","volume":"141","author":"Catargi","year":"1994","journal-title":"European Journal of Endocrinology"},{"key":"2016022218335307000_174.4.491.13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.83.1.40"},{"key":"2016022218335307000_174.4.491.14","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1210\/jc.2003-031172","article-title":"Radioiodine treatment of Graves' hyperthyroidism","volume":"88","author":"Horacek","year":"2003","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2016022218335307000_174.4.491.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021801"},{"key":"2016022218335307000_174.4.491.16","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020805"},{"key":"2016022218335307000_174.4.491.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02841.x"},{"key":"2016022218335307000_174.4.491.18","first-page":"260","article-title":"Dosage determination with radioactive isotopes; practical considerations in therapy and protection","volume":"59","author":"Marinelli","year":"1984","journal-title":"American Journal of Roentgenology and Radium Therapy"},{"key":"2016022218335307000_174.4.491.19","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1007\/s00259-013-2387-x","article-title":"EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases","volume":"40","author":"Hanscheid","year":"2013","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"2016022218335307000_174.4.491.20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/1450-1147.98731","article-title":"Radioiodine thyroid ablation in graves' hyperthyroidism: merits and pitfalls","volume":"11","author":"Nwatsock","year":"2012","journal-title":"World Journal of Nuclear Medicine"},{"key":"2016022218335307000_174.4.491.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01682.x"},{"key":"2016022218335307000_174.4.491.22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031436"},{"key":"2016022218335307000_174.4.491.23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01654.x"},{"key":"2016022218335307000_174.4.491.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(02)00209-6"},{"key":"2016022218335307000_174.4.491.25","doi-asserted-by":"publisher","DOI":"10.1007\/BF00451724"},{"key":"2016022218335307000_174.4.491.26","doi-asserted-by":"crossref","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. 2005 Methods for the Economic Evaluation of Health Care Programmes. pp 1\u2013379. 3rd Edn. Oxford: Oxford University press","DOI":"10.1093\/oso\/9780198529446.003.0001"},{"key":"2016022218335307000_174.4.491.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206253262603"},{"key":"2016022218335307000_174.4.491.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911163212001"},{"key":"2016022218335307000_174.4.491.29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0747"},{"key":"2016022218335307000_174.4.491.30","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1460751"},{"key":"2016022218335307000_174.4.491.31","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1300494"},{"key":"2016022218335307000_174.4.491.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00093-6"},{"key":"2016022218335307000_174.4.491.33","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0521"},{"key":"2016022218335307000_174.4.491.34","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"key":"2016022218335307000_174.4.491.35","doi-asserted-by":"crossref","unstructured":"Spielberger C. 1983 Manual for the State-Trait Anxiety Inventory (form Y). Palo Alto, CA: Consulting Psychologists","DOI":"10.1037\/t06496-000"},{"key":"2016022218335307000_174.4.491.36","unstructured":"Spielberger C, Gorsuch RL, Lushene R. 1970 Manual for the State-Trait Anxiety Inventory (Self-Evaluation Questionnaire). Palo Alto, CA: Consulting Psychologists"},{"key":"2016022218335307000_174.4.491.37","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1117oa"},{"key":"2016022218335307000_174.4.491.38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7094.1580"},{"key":"2016022218335307000_174.4.491.39","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119020-00005"},{"key":"2016022218335307000_174.4.491.40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ejca.2008.09.032","article-title":"Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency","volume":"45","author":"Bottomley","year":"2009","journal-title":"European Journal of Cancer"},{"key":"2016022218335307000_174.4.491.41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.879"},{"key":"2016022218335307000_174.4.491.42","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/eye.2015.76","article-title":"Which factors are associated with quality of life in patients with Graves' orbitopathy presenting for orbital decompression surgery?","volume":"29","author":"Wickwar","year":"2015","journal-title":"Eye"},{"key":"2016022218335307000_174.4.491.43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/4\/491.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/4\/491.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T20:56:17Z","timestamp":1718312177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/174\/4\/491\/6655091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":43,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/eje-15-1099","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}